Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Targeted autoantibody degrader (TRAP subtype of MoDE)

BHV-1420

An investigational treatment for Membranous Nephropathy.

Preclinicalby Biohaven
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify BHV-1420 wherever you encounter it, plus the key facts at a glance.

Generic name
BHV-1420
Development codes
BHV-1420, BHV1420
Drug class
Targeted autoantibody degrader (TRAP subtype of MoDE)
Manufacturer
Biohaven
How it's taken
Expected to be delivered as a subcutaneous (under-the-skin) injection, consistent with Biohaven's other MoDE/TRAP programs.

An investigational subcutaneous autoantibody degrader from Biohaven designed to selectively remove anti-PLA2R (M-type phospholipase A2 receptor) IgG antibodies, the driver of most cases of primary membranous nephropathy, a rare autoimmune kidney disease.

Biohaven described BHV-1420 as still in preclinical development when it presented lab and mouse data on October 24, 2026, and it is part of Biohaven's targeted TRAP autoantibody-degrader portfolio[3][4].

Follow BHV-1420 by email

We'll email you when the FDA acts on BHV-1420 and when new trials for Membranous Nephropathy open. Unsubscribe anytime.

You'll get, for Membranous Nephropathy:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

How BHV-1420 works

Membranous nephropathy is a kidney disease in which the immune system makes an antibody that attacks a protein called PLA2R on the outside of kidney filter cells (podocytes). When the antibody sticks to PLA2R, it forms immune complexes in the kidney's filter, which thickens the filter membrane and lets protein leak into the urine.

Over time this can lead to heavy swelling, high cholesterol, blood clots, and in some patients, kidney failure[6]. BHV-1420 is designed to remove the anti-PLA2R antibody specifically.

Using Biohaven's TRAP technology, the same targeted-degrader idea used for BHV-1400 in IgA nephropathy, one end of the molecule binds anti-PLA2R IgG and the other end attaches to a receptor on the liver. The liver then pulls the antibody in and breaks it down, leaving the rest of the immune system largely intact[4].

Clinical trial results

When checked on November 16, 2026, ClinicalTrials.gov listed no BHV-1420 study and Biohaven's pipeline lists it as preclinical[4]. Biohaven presented the first BHV-1420 data in an oral session at ASN Kidney Week in Denver on October 24, 2026[3]. When BHV-1420 was mixed into blood samples from 59 people who tested positive for anti-PLA2R, 88% of the samples fell below the positive cutoff of a standard clinical test, which suggests it recognizes most patients' antibodies.

In mice given patient-level amounts of the antibody, a single injection under the skin at the highest dose cleared more than 90% of it within 2 hours, and levels stayed down through the 72-hour study[3]. These are laboratory and animal results only. Biohaven has not said when a study in people will start, and it says it is weighing partnerships for newer degrader programs such as BHV-1420[3].

Side effects and safety

Early trial safety observations

No human safety data has been publicly disclosed for BHV-1420 because the program is still preclinical. Its side effects in people will only be known once a study in people begins, and Biohaven has not said when that will be.

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking BHV-1420

Expected to be delivered as a subcutaneous (under-the-skin) injection, consistent with Biohaven's other MoDE/TRAP programs. Dose and frequency will be established in first-in-human studies.

Development history

Membranous nephropathy was a natural next TRAP indication for Biohaven: anti-PLA2R antibody levels track closely with disease activity, treatment response, and relapse risk, giving a clean biomarker for developing a selective degrader. The program builds on Biohaven's existing MoDE/TRAP chemistry and the chemistry already in clinical testing in more advanced programs like BHV-1400 (Gd-IgA1) and BHV-1600 (β1-AR)[4][5].

Ask anything about BHV-1420
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Membranous Nephropathy trials

Other Membranous Nephropathy treatments

Current care for anti-PLA2R-positive membranous nephropathy starts with supportive therapy (ACE inhibitors/ARBs for blood pressure and proteinuria, diuretics, statins, and anticoagulation when the serum albumin is very low), and moves to immunosuppression, typically rituximab (first-line for most patients today) or cyclophosphamide plus steroids, when proteinuria stays high or kidney function declines.

The FDA approved obinutuzumab (Gazyva) for adults with primary membranous nephropathy in November 2026, the first drug approved specifically for the disease[2], and newer approaches in trials include next-generation B-cell-depleting antibodies, complement inhibitors, and autoantibody-specific degraders like BHV-1420. A selective anti-PLA2R degrader could potentially remove circulating pathogenic antibodies faster than B-cell depletion, with less effect on overall immunity[6].

Common questions about BHV-1420

▸What is BHV-1420?

An investigational subcutaneous autoantibody degrader from Biohaven designed to selectively remove anti-PLA2R (M-type phospholipase A2 receptor) IgG antibodies, the driver of most cases of primary membranous nephropathy, a rare autoimmune kidney disease. Biohaven described BHV-1420 as still in preclinical development when it presented lab and mouse data on October 24, 2026, and it is part of Biohaven's targeted TRAP autoantibody-degrader portfolio[3][4].

▸How does BHV-1420 work?

Membranous nephropathy is a kidney disease in which the immune system makes an antibody that attacks a protein called PLA2R on the outside of kidney filter cells (podocytes). When the antibody sticks to PLA2R, it forms immune complexes in the kidney's filter, which thickens the filter membrane and lets protein leak into the urine.

Over time this can lead to heavy swelling, high cholesterol, blood clots, and in some patients, kidney failure[6]. BHV-1420 is designed to remove the anti-PLA2R antibody specifically.

Using Biohaven's TRAP technology, the same targeted-degrader idea used for BHV-1400 in IgA nephropathy, one end of the molecule binds anti-PLA2R IgG and the other end attaches to a receptor on the liver. The liver then pulls the antibody in and breaks it down, leaving the rest of the immune system largely intact[4].

▸What are the side effects of BHV-1420?

No human safety data has been publicly disclosed for BHV-1420 because the program is still preclinical. Its side effects in people will only be known once a study in people begins, and Biohaven has not said when that will be.

▸How is BHV-1420 taken?

Expected to be delivered as a subcutaneous (under-the-skin) injection, consistent with Biohaven's other MoDE/TRAP programs. Dose and frequency will be established in first-in-human studies.

▸Is BHV-1420 FDA approved?

BHV-1420 is currently in preclinical clinical trials for Membranous Nephropathy. It has not yet received FDA approval.

▸When would BHV-1420 reach patients?

BHV-1420 is still preclinical as of October 2026. Biohaven presented lab and mouse results at ASN Kidney Week that month but has not given a date for its first study in people[3]. Gazyva (obinutuzumab), which the FDA approved in November 2026 for adults at risk of the disease getting worse[2], rituximab, cyclophosphamide with steroids, and trials of newer B-cell-depleting antibodies are the options people with membranous nephropathy can ask a nephrologist about today[6].

▸How will we know if BHV-1420 is working in trials?

Anti-PLA2R antibody levels are a well-validated biomarker in membranous nephropathy, they correlate with disease activity, treatment response, and relapse risk. Biohaven has not described a study in people, so the measures a trial would use are not known yet. In its mouse study, Biohaven measured how much of the antibody was cleared from the blood and how fast[3].

▸Why not just use rituximab?

Rituximab is the current first-line biologic for anti-PLA2R-positive membranous nephropathy and works well for many patients, but it takes weeks to lower circulating antibodies, depletes B cells for months, and doesn't help everyone. A selective degrader like BHV-1420 could remove anti-PLA2R antibodies from the bloodstream directly and quickly, without depleting B cells, potentially useful as an alternative for rituximab non-responders or as a faster-acting option before the B-cell-depletion approach has had time to work[6].

▸Is membranous nephropathy rare?

Yes, membranous nephropathy is uncommon, though it is the most common cause of nephrotic syndrome in adults[7]. About 80% of cases have no underlying cause and are called primary membranous nephropathy[7]. In the 2009 study that found the PLA2R antibody, 70% of people with primary membranous nephropathy (26 of 37) had it, and that group is who BHV-1420 is aimed at[8].

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Biohaven (Investor Relations) · 2026-08-10. Biohaven Reports Second Quarter 2026 Financial Results and Recent Business Developments. https://ir.biohaven.com/news-releases/news-release-details/biohaven-reports-recent-business-developments-and-second-quarter
  2. U.S. Food and Drug Administration · 2026-11-13. FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-adults-primary-membranous-nephropathy
  3. Biohaven (Investor Relations) · 2026-10-26. Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy. https://ir.biohaven.com/news-releases/news-release-details/biohaven-oral-presentation-asn-kidney-week-2026-spotlights-bhv
  4. Biohaven · 2025. Biohaven Pipeline, BHV-1420 Membranous Nephropathy Program. https://www.biohaven.com/pipeline/
  5. Biohaven (Investor Relations) · 2022-10-25. Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University. https://ir.biohaven.com/news-releases/news-release-details/biohaven-advances-development-mode-platform-technology-licensed
  6. NephCure Kidney International. Membranous Nephropathy: Patient Overview. https://nephcure.org/membranous-nephropathy/
  7. Nature Reviews Disease Primers · 2021-09-30. Membranous nephropathy. https://pubmed.ncbi.nlm.nih.gov/34593809/
  8. New England Journal of Medicine · 2009-07-02. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. https://pubmed.ncbi.nlm.nih.gov/19571279/

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow BHV-1420 by email

We'll email you when the FDA acts on BHV-1420 and when new trials for Membranous Nephropathy open. Unsubscribe anytime.

You'll get, for Membranous Nephropathy:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site